After graduating at the Gymnasium Markt Schwaben (Bavaria, grade 1.8) in 1998, Markus Hartenbach completed his studies in human medicine at the University of Ulm as part of a career as a medical officer of the German Federal Armed Forces in 2005. From 2005 to 2007 he was admitted to the nuclear medicine section of the Armed Forces Hospital Ulm and received his doctorate degree in 2006 from the University of Ulm on the topic "[11C] choline-PET / CT in primary prostate cancer". During this time he already developed the prospective clinical drug study "Evaluation of choline positron emission tomography, combined by software fusion with magnetic-resonance imaging, in the pre-therapeutic staging of prostate carcinoma" (EudraCT no .: 2006-003933-33; ClinicalTrials .gov no. NCT00520546) and applied successfully to the Federal Institute for Drugs and Medical Devices (BfArM) as well as to the Federal Office for Radiation Protection (BfS) and the Ethics Committee of the University of Ulm. Furthermore, he received third-party funding for this study in the total amount of approx. € 200,000. He completed the certification as principal investigator for clinical studies of the Competence Center Clinical Trials (KKS) of the University of Tübingen. In 2014 he achieved the drug approval for [18F]Fluoroethylcholine for prostate cancer imaging (FEC-Max, Solution for injection) together with the former company E & Z Radiopharma GmbH. This was published in the 2014 Top Journal Clinical Cancer Research (IF 10.2).

2007-2008 he worked as a science officer at the Institute for Radiobiology of the German Federal Armed Forces in Munich. During this time he developed and applied the preclinical cooperation project "Multimodal imaging for the detection, localization and prognostic estimation of an exposure by ionizing irradiation" together with the Ludwig-Maximilians-University Munich, Clinic and Polyclinic for Nuclear Medicine (Medical Director: Prof. Peter Bartenstein) and received € 210,000 in external funding for this project. This project was carried out in the years 2010 to 2013 under his direction at the LMU Munich. In 2008 he received the Golden Cross of Honor for the above mentioned prospective clinical drug study on prostate cancer. In the years 2008-2009 he was promoted to senior medical officer in the nuclear medicine section of the Federal Armed Forces Hospital Ulm, 2010-2011 as a ward physician and expert physician at PET / CT of the Department of Nuclear Medicine of the LMU Munich and 2011-2012 as radiology resident at the Armed Forces Hospital Ulm for CT and MRI training. In 2012, after obtaining the board certification for nuclear medicine, he took over the deputy head position of nuclear medicine at the Federal Armed Forces Hospital Ulm. In the same year, he won the Nuclear Oncology Council's Young Investigator Award from the Society of Nuclear Medicine (SNM 2012, Miami Beach, FL, USA). After parental leave in 2013, he took over the position of the divisional head of the PET / MRI scanner in the clinical department of nuclear medicine at the Vienna General Hospital (Director: Prof. Marcus Hacker). In 2015 he won the Cuno Winkler Prize of the German Society for Nuclear Medicine as the highest prize awarded by the German Society of Nuclear Medicine (DGN). In addition to numerous presentations at national and international congresses (SNM, EANM, DGN, DGHNO) and lecture invitations on PET / MRI in prostate cancer (eg Weill Cornell Medical College, New York, International PET / MRI workshop Tübingen, ECR, SNM) he taught at the MedUniWien incl. doctoral / diploma supervision and the coordination of interdisciplinary research projects on prostate cancer. Since 2013, together with BSM Diagnostika GmbH and Siemens Healthineers, he has developed and applied for the prospective randomized clinical trial "Randomized Assessment of patients with clinically suspected prostate cancer after multiparametric metabolic hybrid imaging to evaluate its potential clinical domain - The RAPID study ", which was approved in 09/2015 by the Austrian Federal Office for Safety in Health Care (BASG) as a Phase III clinical trial. In 2016, he co-founded the Vienna-based Ludwig Boltzmann Institute for Applied Diagnostics (LBI: ad). He also headed the interdisciplinary working group on prostate cancer hybrid imaging and radionuclide therapy at the Medical University of Vienna.

In 2018, together with Prof. Wolfgang Wadsak, he founded the Vienna based MINUTE medical Ltd.

Seit 08/2018	Geschäftsführer der MINUTE medical GmbH Wien
12/2015 und 10/2018	Assistenz- und assoziierter Professor für Nuklearmedizin an der Medizinischen Universität Wien, Österreich
03/2014-10/2018	Oberarzt und Leiter PET / MRT am AKH Wien der Medizinischen Universität Wien, Österreich
01/2013-02/2014	Elternzeit
03/2012-12/2012	Oberarzt und stellvertretender Leiter der Sektion Nuklearmedizin, Bundeswehrkrankenhaus Ulm. Weiterbildung Radiologie am interdisziplinären PET / CT
03/2012	Facharzt für Nuklearmedizin
03/2011-02/2012	Weiterbildung CT / MRT, Klinik für Radiologie, Bundeswehrkrankenhaus Ulm
01/2010-02/2011	Stationsarzt und Weiterbildung PET / CT, Klinik für Nuklearmedizin, Ludwig-Maximilians-Universität München, Campus Großhadern, Ärztlicher Direktor: Prof. Dr. med. P. Bartenstein
12/2009	Leitender Oberarzt und stellvertretender Leiter der Nuklearmedizin, Bundeswehrkrankenhauses Ulm
12/2009	Fachkunde Strahlenschutz
03/2009	Beförderung zum leitenden Oberarzt Bundeswehrkrankenhaus Ulm
12/2008	Goldenes Ehrenkreuz der Bundeswehr
07/2008-12/2009	Assistenzarzt Nuklearmedizinisches Bundeswehrkrankenhaus Ulm
06/2007-06/2008	Wissenschaftlicher Mitarbeiter am Institut für Strahlenbiologie der Bundeswehr in München
11/2006	Zertifizierung Prüfarzt und Studienleiter (Kompetenzzentrum Klinische Studien der Universität Tübingen)
10/2006	Promotion an der Universität Ulm
11/2005-05/2007	Assistenzarzt Nuklearmedizin Bundeswehrkrankenhaus Ulm
11/2005	Hochschulabschluss und Beförderung zum Sanitätsoffizier
10/1999-11/2005	Studium Humanmedizin Universität Ulm
01/1999-09/1999	Offizierlehrgänge I und II in Horb a. Neckar und München
01/1999	Ernennung zum Sanitätsoffizieranwärter
07/1998-12/1998	Wehrdienst in Kempten und München
05/1998	Abitur am Gymnasium Markt Schwaben, Bayern

06/2012              Winner of the Nuclear Oncology Council's Young Investigator Award of the Society of Nuclear Medicine (SNM 2012, Miami Beach, Fla., USA) for the study "FEC-PET / MRI in primary prostate cancer. Results of a prospective clinical trial ".

04/2015              Winner of the Cuno Winkler Prize of the German Society for Nuclear Medicine (DGN) for the publication of the study "Combined PET / MRI Improves Diagnostic Accuracy in Patients with Prostate Cancer: A Prospective Diagnostic Trial".

01/2016              Winner of the BSM-Mallinckrodt-Price of the Austrian Society of Nuclear Medicine and Molecular Imaging (OGNMB)

 

2008-2012         Clinical prospective drug study "Evaluation of choline positron emission tomography, combined by software fusion with magnetic resonance imaging, in the pre-therapeutic staging of prostate carcinoma"; EudraCT no .: 2006-003933-33; ClinicalTrials.gov no. NCT00520546; in cooperation with Eckert & Ziegler EURO-PET Berlin GmbH

2011-2013         Preclinical study "Multimodal imaging for the detection, localization and prognostic estimation of exposure by ionizing irradiation"  in cooperation with the Institute of Radiobiology of the German Armed Forces and the Department of Nuclear Medicine of the LMU Munich.

2015-2020         Clinically prospective randomized Phase III drug trial "Randomized Assessment of patients with clinically suspected prostate cancer after multiparametric metabolic hybrid imaging to evaluate its potential clinical domain - the RAPID study"; EudraCT no .: 2014-004758-33; in cooperation with Siemens Healthcare AG, Eckert & Ziegler Radiopharma Berlin GmbH, BSM Diagnostics GmbH and the Medical University of Vienna (MUW)

2016-2023                         Clinical track of the Ludwig Boltzmann Institute for Applied Diagnostics (LBI:AD) under the lead of Prof. Markus Mitterhauser

Grubmüller B, Baltzer PA, Hartenbach S, D'Andrea D, Helbich TH, Haug A, Goldner G, Wadsak W, Pfaff S, Mitterhauser M, Balber T, Berroterán-Infante N, Grahovac M, Babich JW, Seitz C, Kramer G, Susani M, Mazal P, Kenner L, Shariat SF, Hacker M, Hartenbach M.

PSMA ligand PET/MRI for primary prostate cancer: Staging performance and clinical impact.

Clin Cancer Res. 2018 Aug 23. pii: clincanres.0768.2018. doi: 10.1158/1078-0432.CCR-18-0768. [Epub ahead of print]

 

Rasul S, Hartenbach S, Rebhan K, Göllner A, Karanikas G, Mayerhoefer M, Mazal P, Hacker M, Hartenbach M.

[18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery.

Eur J Nucl Med Mol Imaging. 2018 May 15. doi: 10.1007/s00259-018-4045-9. [Epub ahead of print]

 

Hartenbach M, Weber S, Pilz M, Hartenbach S, Zacherl MJ, Paprottka PM, Tiling R, Bartenstein P, Hacker M, Haug AR, Albert NL.

Combined [18F]-Fluoroethylcholine PET/CT and 99mTc-Macroaggregated Albumin SPECT/CT Predict Survival in Patients With Intermediate-Stage Hepatocellular Carcinoma.

Clin Nucl Med. 2018 Jul;43(7):477-481. doi: 10.1097/RLU.0000000000002092.

 

Grubmüller B, Baltzer P, D'Andrea D, Korn S, Haug AR, Hacker M, Grubmüller KH, Goldner GM, Wadsak W, Pfaff S, Babich J, Seitz C, Fajkovic H, Susani M, Mazal P, Kramer G, Shariat SF, Hartenbach M.

68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making.

Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):235-242. doi: 10.1007/s00259-017-3858-2. Epub 2017 Oct 26.

 

Hartenbach M, Weber S, Albert NL, Hartenbach S, Hirtl A, Zacherl MJ, Paprottka PM, Tiling R, Bartenstein P, Hacker M, Haug AR.

Evaluating treatment response of radioembolization in intermediate stage hepatocellular carcinoma patients using 18Fluoroethylcholine-PET/CT. J Nucl Med. 2015 Nov;56(11):1661-6. doi: 10.2967/jnumed.115.158758. Epub 2015 Sep 24.

 

Hartenbach M, Hartenbach S, Bechtloff W, Danz B, Kraft K, Klemenz B, et al. Combined PET/MRI Improves Diagnostic Accuracy in Patients with Prostate Cancer: A Prospective Diagnostic Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014; 20(12): 3244-53. Journal Highlight Article

 

Associated Highlight Article in:

Nat Rev Urol. 2014 Jun;11(6):306. doi: 10.1038/nrurol.2014.111. Epub 2014 May 13.

Prostate cancer: combined FEC-PET/MRI improves diagnostic accuracy.

Clyne M.

Comment on

Combined PET/MRI improves diagnostic accuracy in patients with prostate cancer: a prospective diagnostic trial. [Clin Cancer Res. 2014]

 

 

Hartenbach M, Delker A, Hartenbach S, Schlichtiger J, Niedermoser S, Wangler C, et al. Dose-Dependent Uptake of 3'-deoxy-3'-[ F]Fluorothymidine by the Bowel after Total-Body Irradiation. Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging. 2014. doi:10.1007/s11307-014-0755-y.

 

 

 

Haug A, Hartenbach M, Hacker M.

Appearances are often deceptive.

Nuklearmedizin. 2018 Aug;57(4):168. doi: 10.1055/s-0038-1668502. Epub 2018 Aug 20.

 

Rischka L, Gryglewski G, Pfaff S, Vanicek T, Hienert M, Klöbl M, Hartenbach M, Haug A, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Hahn A.

Reduced task durations in functional PET imaging with [18F]FDG approaching that of functional MRI.

Neuroimage. 2018 Jun 30;181:323-330. doi: 10.1016/j.neuroimage.2018.06.079. [Epub ahead of print]

 

Leisser A, Nejabat M, Hartenbach M, Agha Mohammadi Sareshgi R, Shariat S, Kramer G, Krainer M, Hacker M, Haug AR.

Analysis of hematological parameters as prognostic markers for toxicity and survival of 223Radium treatment.

Oncotarget. 2018 Mar 5;9(22):16197-16204. doi: 10.18632/oncotarget.24610. eCollection 2018 Mar 23.

 

Leisser A, Nejabat M, Hartenbach M, Duan H, Shariat SF, Kramer G, Krainer M, Hacker M, Haug AR.

Hematopoiesis is prognostic for toxicity and survival of 223Radium treatment in patients with metastatic castration-resistant prostate cancer.

Hell J Nucl Med. 2017 Sep-Dec;20 Suppl:157.

 

Hahn A, Gryglewski G, Nics L, Rischka L, Ganger S, Sigurdardottir H, Vraka C, Silberbauer L, Vanicek T, Kautzky A, Wadsak W, Mitterhauser M, Hartenbach M, Hacker M, Kasper S, Lanzenberger R. Task-relevant brain networks identified with simultaneous PET/MR imaging of metabolism and connectivity.

Brain Struct Funct. 2018 Apr;223(3):1369-1378. doi: 10.1007/s00429-017-1558-0. Epub 2017 Nov 13.

 

Eiber M, Herrmann K, Calais J, Hadaschihk B, Giesel FL, Hartenbach M, Hope TA, Reiter R, Maurer T, Weber WA, Fendler WP. PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT.

J Nucl Med. 2017 Nov 9. pii: jnumed.117.198119. doi: 10.2967/jnumed.117.198119.

 

Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, Gupta P, Hartenbach M, Hope TA, Okamoto S, Pfob CH, Pöppel TD, Rischpler C, Schwarzenböck S, Stebner V, Unterrainer M, Zacho HD, Maurer T, Gratzke C, Crispin A, Czernin J, Herrmann K, Eiber M. 68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study.

J Nucl Med. 2017 Oct;58(10):1617-1623. doi: 10.2967/jnumed.117.190827. Epub 2017 Apr 13.

Rausch I, Rust P, DiFranco MD, Lassen M, Stadlbauer A, Mayerhoefer ME, Hartenbach M, Hacker M, Beyer T. Reproducibility of MRI Dixon-Based Attenuation Correction in Combined PET/MR with Applications for Lean Body Mass Estimation.

J Nucl Med. 2016 Jul;57(7):1096-101. doi: 10.2967/jnumed.115.168294. Epub 2016 Feb 25.

Li X, Heber D, Rausch I, Beitzke D, Mayerhoefer ME, Rasul S, Kreissl M, Mitthauser M, Wadsak W, Hartenbach M, Haug A, Zhang X, Loewe C, Beyer T, Hacker M. Quantitative assessment of atherosclerotic plaques on (18)F-FDG PET/MRI: comparison with a PET/CT hybrid system.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1503-12. doi: 10.1007/s00259-016-3308-6. Epub 2016 Jan 27

 

Leisser A, Pruscha K, Ubl P, Wadsak W, Mayerhöfer M, Mitterhauser M, Hacker M, Kramer G, Shariat S, Karanikas G, Hartenbach M, Haug AR. Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker. Prostate. 2015 Nov;75(15):1760-7. doi: 10.1002/pros.23061. Epub 2015 Aug 18.

Mayerhoefer ME, Giraudo C, Senn D, Hartenbach M, Weber M, Rausch I, Kiesewetter B, Herold CJ, Hacker M, Pones M, Simonitsch-Klupp I, Müllauer L, Dolak W, Lukas J, Raderer M. Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients. Clin Nucl Med. 2015 Sep 22. [Epub ahead of print]

Bailey DL, Pichler BJ, Gückel B, Barthel H, Beer AJ, Bremerich J, Czernin J, Drzezga A, Franzius C, Goh V, Hartenbach M, Iida H, Kjaer A, la Fougère C, Ladefoged CN, Law I, Nikolaou K, Quick HH, Sabri O, Schäfer J, Schäfers M, Wehrl HF, Beyer T. Combined PET/MRI: Multi-modality Multi-parametric Imaging Is Here : Summary Report of the 4th International Workshop on PET/MR Imaging; February 23-27, 2015, Tübingen, Germany. Mol Imaging Biol. 2015 Oct;17(5):595-608. doi: 10.1007/s11307-015-0886-9.

Bailey DL, Barthel H, Beuthin-Baumann B, Beyer T, Bisdas S, Boellaard R, Czernin J, Drzezga A, Ernemann U, Franzius C, Gückel B, Handgretinger R, Hartenbach M, Hellwig D, Nadel H, Nekolla SG, Pfluger T, Pichler BJ, Quick HH, Sabri O, Sattler B, Schäfer J, Schick F, Siegel BA, Schlemmer HP, Schwenzer NF, van den Hoff J, Veit-Haibach P, Wehrl HF.

Combined PET/MR: Where are we now? Summary report of the second international workshop on PET/MR imaging April 8-12, 2013, Tubingen, Germany.

Mol Imaging Biol. 2014 Jun;16(3):295-310. doi: 10.1007/s11307-014-0725-4.

 

Niedermoser S, Pape M, Gildehaus FJ, Wängler C, Hartenbach M, Schirrmacher R, Bartenstein P, Wängler B.

Evaluation of an automated double-synthesis module: efficiency and reliability of subsequent radiosyntheses of FHBG and FLT.

Nucl Med Biol. 2012 May;39(4):586-92. doi: 10.1016/j.nucmedbio.2011.10.018. Epub 2011 Dec 14.

Graute V, Jansen N, Ubleis C, Seitz M, Hartenbach M, Scherr MK, Thieme S, Cumming P, Klanke K, Tiling R, Bartenstein P, Hacker M.

Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy.

Eur J Nucl Med Mol Imaging. 2012 Feb;39(2):271-82. doi: 10.1007/s00259-011-1970-2. Epub 2011 Nov 16.

Dr. Wolfgang Wadsak, an associate professor at the Medical University of Vienna, has a strong scientific focus on medicinal radiochemistry since many years. This resulted in the publication of more than 150 manuscripts in peer-reviewed journals and several book chapters on that topic. He is heading a large research group comprising of multi-discipline multi-level scientists, joint by their efforts in radiotracer development and preclinical testing.

After graduating from Gymnasium Stubenbastei in Vienna in 1990, he completed his civil service at a local paramedics association. Then, he started his studies in chemistry at the University of Vienna and graduated as a master of science in 1999 with distinction. During his PhD thesis, entitled “Evaluation of fluoroethylations using fluorine-18 for the preparation of PET radiopharmaceuticals“, Wolfgang Wadsak started to work cooperatively at the General Hospital of Vienna / Medical University of Vienna. In 2004, he finished his doctorate and graduated as a PhD with distinction. In parallel (2003/04), he also completed a post-graduate course in Radiopharmaceutical Sciences at the Universities in Frankfurt (Germany), ETH Zurich (Switzerland) and Leipzig (Germany) and became trainer/consultant of Bayer AG to teach nuclear medicine departments in the preparation and quality control of the selective radiotherapeutic, 90Y-Zevalin, used in the treatment of Non-Hodgkin lymphoma.

In 2005, Dr. Wadsak successfully completed his education in radiation protection and became the official radiation protection agent for several facilities and entities at the General Hospital / Medical University of Vienna (e.g. Research Labs and PET – Department of Nuclear Medicine; Radiopharmacy – Hospital Pharmacy of the General Hospital; Preclinical Imaging Lab – Department of Biomedical Imaging and Image-guided Therapy). Within the following years, he continued building up a research group with dedicated scientists and pursued his teaching activities and multiple academic institutions. In 2009, he passed his habilitation in Medicinal Radiochemistry and was awarded with the venia docendi by the Medical University of Vienna. He continued the tenure track as assistant professor, completed a 4-month scientific internship at ETH Zurich, one of the world’s top academic institutions in the field, and successfully finished his qualification agreement in 2012, when he was promoted into the rank of an Associate Professor.

In 2015, Assoc.-Prof. Wolfgang Wadsak joined the Board of Directors in the Austrian Society for Nuclear Medicine and Molecular Imaging (OGNMB) and was appointed Secretary/Treasurer in 2016. In the same year, he founded the Alliance for the Promotion of the Radiopharmaceutical Sciences together with Markus Mitterhauser and joined the “Center for Biomarker Research in Medicine” (CBmed), a research center of excellence funded by the Austrian government with its HQ in Graz. There, he took over the coordination of all Vienna based activities as well as the lead in the Area “Data & Technologies”. This encompasses diverse wet-lab techniques (e.g. NGS, metabolomics, MALDI-MS, immunology assays and digital pathology) and data-driven approaches to enrich biomarker discovery, validation and translation.

In 2018, together with Prof. Markus Hartenbach, he founded the Vienna based MINUTE medical Ltd. Wolfgang Wadsak is married and father of four children.

Seit 01/2019	Sekretär/Schatzmeister der European Association of Nuclear Medicine (EANM)
Seit 2017	Scientific Leader – Area 1 (Data & Technologies), CBmed Ltd (Center for Biomarker Research in Medicine; Graz)
Seit 10/2016	Koordinator der Vienna Activities, Projects and Labs, CBmed Ltd (Center for Biomarker Research in Medicine; Graz)
Seit 2016	Sicherheitsvertrauensperson
Seit 2016	Sekretär/Schatzmeister der Österreichischen Gesellschaft für Nuklearmedizin und Molekulare Bildgebung (OGNMB)
Seit 2016	Direktor der „Allianz zur Förderung der Radiopharmazeutischen Wissenschaften“
Seit 2015	Auditor der European Association of Nuclear Medicine (EANM)
Seit 2015	Vorstandsmitglied der Österreichischen Gesellschaft für Nuklearmedizin und Molekulare Bildgebung (OGNMB)
Seit 2013	Leiter des „Development of Imaging Probes“-Knotens im Medical Imaging Cluster (MIC) @MedUni Wien
Seit 2012	Assoziierter Professor für Medizinische Radiochemie, Leiter der Abteilung Medizinische Radiochemie und Biomarkerentwicklung, Medizinische Universität Wien
2011	4-monatiges wissenschaftliches Praktikum an der ETH Zürich, Schweiz
2010-2012	Assistenzprofessor, Abteilung Radiochemie und Biomarkerentwicklung, Medizinische Universität Wien
2009-2010	Senior Post-Doc, Medizinische Universität Wien
Seit 2009	Lehrbeauftragter für „Physiology and Pathology for Functional Imaging 1“ an der Fachhochschule Wiener Neustadt (Masterstudiengang „MedTech“)
2009	Habilitation; Medizinische Radiochemie, Medizinische Universität Wien
Seit 2005	Strahlenschutzbeauftragter – Labore für Radiochemie, Radiopharmazie, Psychiatrie und Labor für präklinische Bildgebung (PIL)
Seit 2005	Lektor für „Medizinische Radiochemie 1+2“ an der Universität Wien
Seit 2004	Trainer und Berater der Bayer AG (ehemals Schering AG), Wien für Radioimmuntherapie
Seit 2003	Lektor für „Radiopharmazie“ an der Akademie für Radiologietechnologen in Wien (jetzt: FH Wien)
2003-2004	Nachdiplomstudium in Radiopharmazeutischer Chemie, ETH Zürich/ Universitäten Frankfurt und Leipzig
Seit 2001	Produktionsleiter für PET-Radiopharmaka, Universitätsklinik für Nuklearmedizin, Medizinische Universität Wien
2001-2009	Universitätsassistent, Medizinische Universität Wien
2000-2004	Promotionsstudium (Radiochemie), Universität Wien und wissenschaftlicher Mitarbeiter, Universitätsklinik für Nuklearmedizin, Medizinische Universität Wien
1991-1999	Masterstudium Chemie, Universität Wien

From 2016          Co-PI of the WWTF grant # CS15-033 (total volume: >590k€)

From 2015          Co-PI of the EU Eurostars-2 grant #E!9669 ATRI (national funding agency: FFG; total volume: >1.4M€)

Since 2007          Project manager of >10 industry sponsored research projects (total volume: >600k€)

2006 & 2008      THP Award for Basic Sciences in Nuclear Medicine

2002-2007           Project manager for the project #8263 (Jubilaeumsfonds of the Austrian Federal Bank; total volume: >35k€)

2004      Winner of the Scholarship „Dr. Pfeiffer-Stipendium“, Austrian Society for Nuclear Medicine and Molecular Imaging (OGN)

Since 2003          Co-investigator in multiple Austrian Science Fund, Austrian Federal Bank or industry sponsored projects (total volume: >4.1M€)

998 Scholarship for extraordinary achievements, University of Vienna

key figures (as of 01/01/2019):

158 total peer-reviewed publications (thereof: 152 articles, 2 reviews & 3 book-chapters);

2700 total cites;

h-factor: 28

 

*)            Wadsak W and Mitterhauser M. Synthesis of [18F]FETO, a novel potential 11-β hydroxylase inhibitor. Journal of Labelled Compounds and Radiopharmaceuticals 2003; 46:379-388.

*)           Becherer A, Karanikas G, Szabó M, Georg G, Asenbaum S, Marosi C, Henk C, Wunderbaldinger P, Czech T, Wadsak W, Kletter K. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine.  European Journal of Nuclear Medicine and Molecular Imaging 2003; 30: 1561-1566.

*)           Wadsak W, Mitterhauser M, Mien LK, Tögel S, Keppler B, Dudczak R, Kletter K. Radiosynthesis of 3-(2‘-[18F]Fluoro)-flumazenil ([18F]FFMZ). Journal of Labelled Compounds and Radiopharmaceuticals 2003; 46:1229-1240.

*)           Zetting G, Mitterhauser M, Wadsak W, Becherer A, Pirich C, Vierhapper H, Niederle B, Dudczak R, Kletter K. Positron emission tomography imaging of adrenal masses: F-18 Fluordesoxyglucose and the 11-beta hydroxylase-tracer C-11-metomidate. European Journal of Nuclear Medicine and Molecular Imaging 2004; 31: 1224-1230.

*)           Brunner M, Langer O, Dobrozemsky G, Müller U, Zeitlinger M, Mitterhauser M, Wadsak W, Dudczak R, Kletter K, Müller M. [18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of Ciprofloxacin in humans. Antimicrobial Agents and Chemotherapy 2004;48: 3850-3857.

*)           Wadsak W, Wirl-Sagadin B, Mitterhauser M, Mien LK, Ettlinger DE, Dudczak R, Kletter K. N.c.a. nucleophilic radiofluorination on substituted benzaldehydes for the preparation of [18F]fluorinated aromatic amino acids. Applied Radiation and Isotopes 2006; 64:355-359.

*)            Wadsak W, Mitterhauser M, Rendl G, Schuetz M, Mien LK, Ettlinger DE, Dudczak R, Kletter K, Karanikas G. [18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers.     European Journal of Nuclear Medicine and Molecular Imaging 2006; 33:669-672.

*)           Ettlinger DE, Wadsak W, MienLK, Machek M, Wabnegger L, Rendl G, Karanikas G, Viernstein H, Kletter K,  Dudczak R, Mitterhauser M. [18F]FETO: metabolic considerations. European Journal of Nuclear Medicine and Molecular Imaging 2006; 33: 928-931.

*)           Mitterhauser M, Dobrozemsky G, Zettinig G, Wadsak W, Vierhapper H, Dudczak R, Kletter K.      Imaging of adrenocortical metastases with [11C]metomidate. European Journal of Nuclear Medicine and     Molecular Imaging 2006; 33: 974.

*)           Mitterhauser M and Wadsak W. [18F]FETO - a longer lived PET tracer for the measurement of 11-beta-hydroxylase activity. Journal of Clinical Endocrinology and Metabolism 2006; e-letter.

*)            Mitterhauser M and Wadsak W. Evaluation of novel tropane analogues. Nuclear Medicine and Biology 2007; 34: 591-592.

*)           Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, Holik A, Attarbaschi T, Mossaheb N, Sacher J, Geiss-Granadia T, Kletter K, Kasper S, Tauscher J. Reduced serotonin-1A receptor binding in social anxiety disorder. Biological Psychiatry 2007; 61: 1081-1089.

*)           Wadsak W, Mien LK, Ettlinger DE, Feitscher S, Lanzenberger R, Marton J, Dudczak R, Kletter K, Mitterhauser M. Preparation and Radiosynthesis of [18F]FE@CFN (2-[18F]fluoroethyl 4-[N-(1-oxopropyl)-N-phenylamino]-1-(2-phenylethyl)-4-piperidinecarboxylate), a Potential µ-Opioid Receptor Imaging Agent. Radiochimica Acta 2007; 95:33-38.

*)           Wadsak W, Mien LK, Ettlinger DE, Lanzenberger R, Haeusler D, Dudczak R, Kletter K, Mitterhauser M. Simple and fully automated preparation of [carbonyl-11C]WAY-100635. Radiochimica Acta 2007; 95:417-422.

*)           Wadsak W, Mien LK, Ettlinger DE, Eidherr H, Haeusler D, Sindelar KM, Keppler BK, Dudczak R, Kletter K, Mitterhauser M. [18F]Fluoroethylations: Different strategies for the rapid translation of [11C]methylated Radiotracers. Nuclear Medicine and Biology 2007; 34:1019-1028.

*)           Wadsak W, Mien LK, Shanab K, Ettlinger DE, Haeusler D, Sindelar KM, Lanzenberger RR, Spreitzer H, Viernstein H, Keppler BK, Dudczak R, Kletter K, Mitterhauser M. Preparation and first evaluation of [18F]FE@SUPPY: a new PET-Tracer for the Adenosine A3 Receptor. Nuclear Medicine and Biology 2008; 35:61-66.

*)           Wadsak W, Mien LK, Shanab K, Weber K, Schmidt B, Sindelar KM, Ettlinger DE, Haeusler D, Spreitzer H, Keppler BK, Viernstein H, Dudczak R, Kletter K, Mitterhauser M. Radiosynthesis of the adenosine A3 receptor ligand 5-(2-[18F]fluoroethyl) 2,4-diethyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([18F]FE@SUPPY). Radiochimica Acta 2008; 96:119-124.

*)           Spindelegger C, Lanzenberger R, Wadsak W, Mien LK, Stein P, Mitterhauser M, Moser U, Holik A, Kletter K, Kasper S. Influence of escitalopram treatment on 5-HT1A receptor binding in limbic regions in patients with anxiety disorders. Molecular Psychiatry 2009;14: 1040-50.

*)            Haeusler D, Mien LK, Nics L, Ungersboeck J, Philippe C, Lanzenberger RR, Kletter K, Dudczak R, Mitterhauser M, Wadsak W. Simple and rapid preparation of [11C]DASB with high quality and reliability for routine applications. Applied Radiation and Isotopes 2009; 67:1654-1660.

*)            Haeusler D, Mitterhauser M, Mien LK, Shanab K, Lanzenberger RR, Schirmer E, Ungersboeck J, Nics L, Spreitzer H, Viernstein H, Dudczak R, Kletter K, Wadsak W. Radiosynthesis of a novel potential adenosine A3 receptor ligand, 5-ethyl 2,4-diethyl-3-((2-[18F]fluoroethyl)sulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([18F]FE@SUPPY:2). Radiochimica Acta 2009; 97:753-758.

*)           Mitterhauser M, Haeusler D, Mien LK, Ungersboeck J, Nics L, Lanzenberger R, Sindelar K, Viernstein H, Dudczak R, Kletter K, Spreitzer H, Wadsak W. Automatisation and first evaluation of [18F]FE@SUPPY:2, an alternative PET-Tracer for the Adenosine A3 Receptor: A Comparison with [18F]FE@SUPPY. The Open Nuclear Medicine Journal 2009; 1:15-23.

*)            Wadsak W and Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. European Journal of Radiology 2010; 73:461-469.

*)           Ungersboeck J, Philippe C, Mien LK, Haeusler D, Shanab K, Lanzenberger R, Spreitzer H, Keppler BK, Dudczak R, Kletter K, Mitterhauser M, Wadsak W. Microchemical Preparation of [18F]FE@SUPPY and [18F]FE@SUPPY:2 – comparison with conventional radiosyntheses. Nuclear Medicine and Biology 2011; 38:427-434.

*)           Philippe C, Haeusler D, Mitterhauser M, Ungersboeck J, Viernstein H, Dudczak R, Wadsak W. Optimization of the radiosynthesis of the Alzheimer tracer 2-(4-N-[11C]methylaminophenyl)-6-hydroxybenzothiazole ([11C]PIB). Applied Radiation and Isotopes 2011; 69:1212-1217.

*)           Selivanova SV, Mu L, Ungersboeck J, Stellfeld T, Ametamey SM, Schibli R, Wadsak W. Single-step radiofluorination of peptides using continuous flow microreactor. Organic and Biomolecular Chemistry 2012; 10: 3871-3874.

*)           Ungersboeck J, Richter S, Collier TL, Mitterhauser M, Karanikas G, Lanzenberger R, Dudczak R, Wadsak W.

Radiolabelling of [18F]altanserin – a microfluidic approach. Nuclear Medicine and Biology 2012; 39:1087-1092.

*)           Philippe C, Schirmer E, Mitterhauser M, Shanab K, Spreitzer H, Viernstein H, Wadsak W. Radiosynthesis of [11C]SNAP-7941 – the first PET-Tracer for the Melanin Concentrating Hormone Receptor 1 (MCHR1). Applied Radiation and Isotopes 2012; 70:2287–2294.

*)           Ungersboeck J, Philippe C, Haeusler D, Mitterhauser M, Lanzenberger R, Dudczak R, Wadsak W. Optimization of [11C]DASB-synthesis: microfluidic and vessel-based methods. Applied Radiation and Isotopes 2012; 70:2615–2620.

*)           Philippe C, Ungersboeck J, Schirmer E, Zdravkovic M, Shanab K, Lanzenberger R, Spreitzer H, Viernstein H, Mitterhauser M, Wadsak W. [18F]FE@SNAP - a new PET tracer for the Melanin Concentrating Hormone Receptor 1 (MCHR1): microfluidic and vessel-based approaches. Bioorganic and Medicinal Chemistry 2012; 20:5936-5940.

*)           Hahn A, Wadsak W, Windischberger C, Baldinger P, Höflich A, Losak J, Nics L, Philippe C, Kranz G, Kraus C, Mitterhauser M, Karanikas G, Kasper S, Lanzenberger R. Differential modulation of the default mode network via serotonin-1A receptors. Proceedings of the National Academy of Sciences of the USA 2012;109:2619-24.

*)           Mayerhoefer ME, Ba-Ssalamah A, Weber M, Mitterhauser M, Eidherr H, Wadsak W, Trattnig S, Herneth A, Karanikas G. Gadoxetate-enhanced versus Diffusion-weighted MRI for Fused 68Ga-DOTANOC PET/MRI in Patients with Neuroendocrine Tumors of the Upper Abdomen. European Radiology 2013;23:1978-85.

*)           Toth DF, Raderer M, Wadsak W, Karanikas G. Beta-2 Microglobulin as a Diagnostic Parameter in Non-Hodgkin Lymphoma: A Comparative Study with FDG-PET. Anticancer Research 2013;33:3341-3345.

*)            Mark C, Bornatowicz B, Nics L, Haeusler D, Hendl M, Berger M, Lanzenberger R, Karanikas G, Spreitzer H,, Mitterhauser M, Wadsak W. Development and evaluation of a novel PET tracer for the norepinephrine transporter: [11C]Me@APPI. Nuclear Medicine and Biology 2013; 40:295-303.

*)           Rami-Mark C, Ungersboeck J, Haeusler D, Nics L, Philippe C, Mitterhauser M, Willeit M, Lanzenberger R, Karanikas G, Wadsak W. Reliable set-up for in-loop 11C-carboxylations using Grignard reactions for the preparation of [carbonyl-11C]WAY-100635 and [11C]-(+)-PHNO. Applied Radiation and Isotopes 2013; 82:75-80.

*)            Rami-Mark C, Zhang MR, Mitterhauser M, Lanzenberger R, Hacker M, Wadsak W. [18F]FMeNER-D2: Reliable fully-automated synthesis for clinical visualization of the norepinephrine transporter. Nuclear Medicine and Biology 2013;40:1049-1054.

*)            Rami-Mark C, Bornatowicz B, Fink C, Otter P, Ungersboeck J, Vraka C, Haeusler D, Nics L, Spreitzer H, Hacker M, Mitterhauser M, Wadsak W. Synthesis, radiosynthesis and first in-vitro evaluation of novel PET-tracers for the dopamine transporter: [11C]IPCIT and [18F]FE@IPCIT. Bioorganic and Medicinal Chemistry 2013; 21:7562-7569.

*)            Mitterhauser M and Wadsak W. Imaging Biomarkers or Biomarker Imaging? Pharmaceuticals 2014;7:765-778.

*)           Vanicek T, Spies M, Rami-Mark C, Savli M, Höflich A, Kranz GS, Hahn A, Kutzelnigg A, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Volkow N, Kasper S, Lanzenberger R. The norepinephrine transporter in attention deficit and hyperactivity disorder investigated with (S,S)-[18F]FMeNER-D2. JAMA Psychiatry 2014;71:1340-9.

*)           Leisser A, Pruscha K, Ubl P, Wadsak W, Mayerhöfer M, Mitterhauser M, Hacker M, Kramer G, Shariat S, Karanikas G, Hartenbach M, Haug A.R. Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [11C]acetate PET as a prognostic marker. The Prostate 2015;75:1760-7.

*)           Spick C, Polanec S, Mitterhauser M, Wadsak W, Anner P, Reiterits B, Haug AR, Hacker M, Beheshti M, Karanikas G. Detection of Bone Metastases Using 11C-Acetate PET in Patients with Prostate cancer with Biochemical Recurrence. Anticancer Research 2015;35:6787-91.

*)           Philippe C, Zeilinger M, Mitterhauser M, Dumanic M, Lanzenberger R, Hacker M, Wadsak W. Parameter evaluation and fully-automated radiosynthesis of [11C]harmine for imaging of MAO-A for clinical trials. Applied Radiation and Isotopes 2015; 97:182–187.

*)           Rami-Mark C, Berroterán-Infante N., Philippe C, Foltin S, Vraka C, Hoepping A, Lanzenberger R, Hacker M, Mitterhauser M*, Wadsak W*. Radiosynthesis and first preclinical evaluation of the novel norepinephrine transporter PET-Ligand [11C]Me@HAPTHI. European Journal of Nuclear Medicine and Molecular Imaging Research 2015;5(1):113.

*)           Rami-Mark C, Eberher N, Berroterán-Infante N, Vanicek T, Nics L, Lanzenberger R, Hacker M, Wadsak W*, Mitterhauser M*. [18F]FMeNER-D2: A systematic in vitro analysis of radio-metabolism. Nuclear Medicine and Biology 2016;43:490-495.

*)           Sigurdardottir HL, Kranz GS, Rami-Mark C, James GM, Vanicek T, Gryglewski G, Hienert M, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Rujescu D, Kasper S, Lanzenberger R. Effects of norepinephrine transporter gene variants on NET binding in ADHD and healthy controls investigated by PET. Human Brain Mapping 2016;37:884-95.

*)           Wenzel B, Mollitor J, Deuther-Conrad W, Dukic-Stefanovic S, Kranz M, Vraka C, Teodoro R, Günther R, Donat C, Ludwig FA, Fischer S, Smits R, Wadsak W, Mitterhauser M, Steinbach J, Hoepping A, Brust P. On the development of a novel non-peptidic 18F-labeled radiotracer for in vivo imaging of oxytocin receptors with positron emission tomography. Journal of Medicinal Chemistry 2016;59(5):1800-17.

*)           Philippe C, Haeusler D, Scherer T, Fuernsinn C, Zeilinger M, Wadsak W, Shanab K, Spreitzer H, Hacker M, Mitterhauser M. [18F]FE@SNAP – a specific PET-tracer for melanin-concentrating hormone receptor 1 imaging? EJNMMI Research 2016; 6:31.

*)           Li X, Heber D, Rausch I, Beitzke D, Mayerhoefer ME, Rasul S, Kreissl M, Mitterhauser M, Wadsak W, Hartenbach M, Haug A, Zhang X, Loewe C, Beyer T, Hacker M. Quantitative assessment of atherosclerotic plaques on 18F-FDG PET/MRI: comparison with a PET/CT hybrid system. European Journal of Nuclear Medicine and Molecular Imaging 2016;43:1503-12.

*)           Bauer M, Römermann K, Karch R, Wulkersdorfer B, Stanek J, Philippe C, Maier-Salamon A, Haslacher H, Jungbauer C, Wadsak W, Jäger W, Löscher W, Hacker M, Zeitlinger M, Langer O. A pilot PET study to assess the functional interplay between P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier.  Clinical Pharmacology & Therapeutics 2016;100:131-41.

*)           Bauer M, Blaickner M, Philippe C, Wadsak W, Hacker M, Zeitlinger M, Langer O. Whole-body Distribution and Radiation Dosimetry of 11C-Elacridar and 11C-Tariquidar in Humans. Journal of Nuclear Medicine 2016;57:1265-8.

*)            Leithner D, Baltzer PA, Magometschnigg HF, Wengert GJ, Karanikas G, Helbich TH, Weber M, Wadsak W, Pinker K.  Quantitative Assessment of Breast Parenchymal Uptake in [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Correlation with Age, Background Parenchymal Enhancement, and Amount of Fibroglandular Tissue on Magnetic Resonance Imaging. Journal of Nuclear Medicine 2016;57:1518-1522.

*)            Pinker K, Andrzejewski P, Baltzer P, Polanec S, Sturdza A, Georg D, Helbich TH, Karanikas G, Grimm C, Polterauer S, Poetter R, Wadsak W, Mitterhauser M, Georg P.  Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-invasive Detection of Tumor Heterogeneity: A Pilot Study. PlosOne 2016;11(5):e0155333.

*)           Vanicek T, Hahn A, Traub-Weidinger T, Hilger E, Spies M, Wadsak W, Lanzenberger R, Pataraia E, Asenbaum-Nan S. Differences in metabolic network connectivity in left- and right-sided mesial temporal lobe epilepsy using with [18F]FDG PET. Scientific Reports 2016;6:28513.

*)           Traub-Weidinger T, Weidinger P, Gröppel G, Karanikas G, Wadsak W, Kasprian G, Dorfer C, Dressler A, Muehlebner A, Hacker M, Czech T, Feucht M. Presurgical evaluation of pediatric epilepsy patients prior to hemispherotomy: the prognostic value of 18F-FDG PET. J Neurosurg Pediatr. 2016;25:683-688.

*)           Hahn A, Gryglewski G, Nics L, Hienert M, Rischka L, Vraka C, Sigurdardottir H, Vanicek T, James G, Seiger R, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R. Quantification of task-specific glucose metabolism with constant infusion of [18F]FDG. Journal of Nuclear Medicine 2016;57:1933-1940.

*)           Steiner E, Kazianka L, Breuer R, Hacker M, Wadsak W, Mitterhauser M, Stimpfl T, Reiter B, Karanikas G, Miholic J. **-Postprandial pancreatic [11C]methionine uptake after pancreaticoduodenectomy mirrors basal beta cell function and insulin release. European Journal of Nuclear Medicine and Molecular Imaging 2017;44:509-516.

*)           Bauer M, Karch R, Tournier N, Cisternino S, Wadsak W, Hacker M, Marhofer P, Zeitlinger M, Langer O.  Assessment of P-glycoprotein Transport Activity at the Human Blood-Retinal Barrier with (R)-11C-verapamil PET.  J Nucl Med. 2017;58:678-681.

*)           Komorowski A, James GM, Philippe C, Gryglewski G, Bauer A, Hienert M, Spies M, Kautzky A, Vanicek T, Hahn A, Traub-Weidinger T, Winkler D, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R. Association of protein distribution and gene expression revealed by PET and post-mortem quantification in the serotonergic system of the human brain. Cerebral Cortex 2017;27:117-130.

*)           Vanicek T, Kutzelnigg A, Philippe C, Sigurdardottir HL, James GM, Hahn A, Kranz GS, Höflich A, Kautzky A, Traub-Weidinger T, Hacker M, Wadsak W, Mitterhauser M, Kasper S, Lanzenberger R. Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET. Human Brain Mapping 2017;38:792-802.

*)           Gryglewski G, Rischka L, Philippe C, Hahn A, James GM, Klebermass E, Hienert M, Silberbauer L, Vanicek T, Kautzky A, Berroterán-Infante N, Nics L, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Lanzenberger R. Simple and rapid quantification of serotonin transporter binding using [11C]DASB bolus plus constant infusion. Neuroimage 2017; 149:23–32.

*)           Vraka C, Nics L, Wagner KH, Hacker M, Wadsak W, Mitterhauser M. LogP, a yesterday's value? Nucl Med Biol. 2017;50:1-10.

*)           Zeilinger M, Pichler F, Nics L, Wadsak W, Spreitzer H, Hacker M, Mitterhauser M. New approaches for the reliable in-vitro assessment of binding affinity based on high-resolution real-time data acquisition of radioligand-receptor binding kinetics. EJNMMI Research 2017;7:22.

*)           James GM, Baldinger-Melich P, Philippe C, Kranz GS, Vanicek T, Hahn A, Gryglewski G, Hienert M, Spies M,  Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Lanzenberger R. Effects of selective serotonin reuptake inhibitors on interregional relation of serotonin transporter availability in major depression. Frontiers in Human Neuroscience 2017;11:48.

*)           Li S, Peck-Radosavljevic M, Ubl P, Wadsak W, Mitterhauser M, Rainer E, Pinter M, Wang H, Nanoff C, Kaczirek K, Haug A, Hacker M. The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab. European Journal of Nuclear Medicine and Molecular Imaging 2017;44:1732-1741.

*)           Kautzky A, James GM, Philippe C, Baldinger-Melich P, Kraus C, Kranz GS, Vanicek T, Gryglewski G, Wadsak W, Mitterhauser W, Rujescu D, Kasper S, Lanzenberger R. The influence of the rs6295 gene polymorphism on serotonin-1A receptor distribution investigated with PET in patients with major depression applying machine learning. Translational Psychiatry 2017;7:e1150.

*)           Polanec SH, Andrzejewski P, Baltzer PAT, Helbich TH, Stiglbauer A, Georg D, Karanikas G, Susani M, Wadsak W, Margreiter M, Mitterhauser M, Brader P, Pinker K. Multiparametric [11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer. PLoS One 2017;12(7):e0180790.

*)           Lassen ML,  Muzik O, Beyer T, Hacker M, Ladefoged CN, Cal-Gonzalez J, Wadsak W, Rausch I,  Langer O, Bauer M. Reproducibility of a quantitative brain PET protocol in PET-only and combined PET/MR imaging.  Frontiers in Neuroscience 2017;11:396.

*)            Ahmadi Y, Kostenich G, Oron-Herman M,  Wadsak W, Mitterhauser M, Orenstein A, Mirzaei S, Knoll P.  In vivo magnetic resonance imaging of pancreatic tumors using iron oxide nanoworms targeted with PTR86 peptide. Colloids and Surfaces B 2017;158:423-430.

*)           Zeilinger M, Dumanic M, Pichler F, Budinsky L, Wadsak W, Pallitsch K, Spreitzer H, Lanzenberger R, Hacker M, Mitterhauser M, Philippe C. In vivo evaluation of radiotracers targeting the melaninconcentrating hormone receptor 1: [11C]SNAP-7941 and [18F]FE@SNAP reveal specific uptake in the ventricular system. Scientific Reports 2017; 14;7:8054.

*)           Bauer M, Wulkersdorfer B, Karch R, Philippe C, Jäger W, Stanek J, Wadsak W, Hacker M, Zeitlinger M, Langer O. Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[11C]verapamil in elderly versus young subjects. British Journal of Clinical Pharmacology 2017;83:1991-1999.

*)           Daniel M, Andrzejewski P, Sturdza A, Majercakova K, Baltzer P, Pinker K, Wadsak W, Mitterhauser M, Pötter R, Georg P, Helbich T, Georg D. Impact of hybrid PET/MR technology on multiparametric imaging and treatment response assessment of cervix cancer. Radiother Oncol. 2017;125:420-425.

*)           Fazekas J, Berroterán-Infante N, Rami-Mark C, Dumanic M, Matz M, Willmann M, Andreae F, Singer J, Wadsak W, Mitterhauser M, Jensen-Jarolim E. Development of a radiolabeled caninized anti-EGFR antibody for comparative oncology trials. Oncotarget 2017;8(47):83128-83141.

*)           Georg P, Andrzejewski P, Baltzer P, Daniel M, Wadsak W, Mitterhauser M, Sturdza A, Majercakova K, Karanikas G, Pötter R, Hacker M, Helbich T, Georg D, Pinker K. Changes in tumor biology during chemoradiation of cervix cancer assessed by multiparametric MRI and hypoxia PET. Molecular Imaging and Biology 2018;20(1):160-169.

*)           Nakuz TS, Berger E, El-Rabadi K, Wadsak W, Haug A, Hacker M, Karanikas G. Clinical Value of 18F-FDOPA PET/CT With Contrast Enhancement and Without Carbidopa Premedication in Patients with Insulinoma. Anticancer Res. 2018;38:353-358.

*)           Azizi A, Slavc I, Peyrl A, Rausch I, Theisen BE, Benkoe T, Aszmann O, Wadsak W, Weber M, Amann G, Kasprian G, Hojreh A, Hacker M, Staudenherz A, Traub-Weidinger T. Monitoring of Plexiform Neurofibroma in Children and Adolescents with Neurofibromatosis Type 1 by [18F]FDG-PET imaging. Is it of value in asymptomatic patients? Pedriatic Blood and Cancer 2018;65(1).

*)           Grubmüller B, Baltzer P, D'Andrea D, Korn S, Haug AR, Hacker M, Grubmüller KH, Goldner GM, Wadsak W, Pfaff S, Babich J, Seitz C, Fajkovic H, Susani M, Mazal P, Kramer G, Shariat SF, Hartenbach M. 68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making. Eur J Nucl Med Mol Imaging. 2018;45:235-242.

*)           Li X, Heber D, Leike T, Beitzke D, Lu X, Zhang X, Wei Y, Mitterhauser M, Wadsak W, Kropf S, Wester HJ, Loewe C, Hacker M, Haug AR. [68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques. Eur J Nucl Med Mol Imaging. 2018;45:558-566.

*)           Poetsch N, Woehrer A, Gesperger J, Furtner J, Haug AR, Wilhelm D, Widhalm G, Karanikas G, Weber M,  Rausch I, Mitterhauser M, Wadsak W, Hacker M, Preusser M, Traub-Weidinger T. Visual and semiquantitative 11C-methionine PET: An independent prognostic factor for characterization of newly diagnosed and treatment naive gliomas. Neuro Oncol. 2018;20:411-419.

*)           Bauer M, Matsuda A, Wulkersdorfer B, Philippe C, Traxl A, Özvegy-Laczka C, Stanek J, Nics L, Klebermass EM,  Poschner S, Jaeger W, Patik I, Bakos E, Szakács G, Wadsak W, Hacker M, Zeitlinger M, Langer O. Influence of OATPs on hepatic disposition of erlotinib measured with positron emission tomography.  Clin Pharmacol Ther. 2018;104:139-147.

*)           Papp L, Poetsch N, Grahovac M, Schmidbauer V, Woehrer A, Preusser M, Mitterhauser M, Kiesel B, Wadsak W, Beyer T, Hacker M, Traub-Weidinger T.  Glioma survival prediction with the combined analysis of in vivo 11C-MET-PET, ex  vivo and patient features by supervised machine learning. J Nucl Med. 2018;59:892-899.

*)           Hahn A, Gryglewski G, Nics L, Rischka L, Ganger S, Sigurdardottir H, Silberbauer L, Vanicek T, Kautzky A, Wadsak W, Mitterhauser M, Hartenbach M, Hacker M, Kasper S, Lanzenberger R. Task-relevant brain networks identified with simultaneous PET/MR imaging of metabolism and connectivity. Brain Structure and Function 2018;223:1369-1378.

*)           Kranz GS, Hahn A, Kraus C, Spies M, Pichler V, Jungwirth J, Mitterhauser M, Wadsak W, Windischberger C, Kasper S, Lanzenberger R. Probing the association between serotonin-1A autoreceptor binding and amygdala reactivity in healthy volunteers. NeuroImage 2018;171:1-5.

*)           Anner P, Mayerhöfer M, Wadsak W, Dudczak R, Haug A, Hacker M, Karanikas G. [18F]FDG-PET/CT and MRI for initial pelvic lymph node staging in patients with cervical carcinoma - potential usefulness of [18F]FDG-PET/MRI. Oncol Lett. 2018;15:3951-3956.

*)            Vraka C, Mijailovic S, Fröhlich V, Zeilinger M, Klebermass EM, Wadsak W, Wagner KH, Hacker M, Mitterhauser M. Expanding LogP: Present possibilities. Nucl Med Biol 2018;58:20-32.

*)           Vraka C, Dumanic M, Racz T, Pichler F, Balber T, Philippe C, Klebermass EM, Wagner KH, Hacker M, Wadsak W, Mitterhauser M. A new Method Measuring the Interaction of Radiotracers with the human P-glycoprotein (P-gp) Transporter. Nucl Med Biol. 2018;60:29-36.

*)           Balber T, Singer J, Berroterán-Infante N, Dumanic M, Fetty L, Fazekas-Singer J, Vraka C, Nics L, Bergmann M, Pallitsch K, Spreitzer H, Wadsak W, Hacker M, Jensen-Jarolim E, Viernstein H, Mitterhauser M. Preclinical in vitro and in vivo evaluation of [18F]FE@SUPPY for cancer PET-imaging: Limitations of a xenograft model for colorectal cancer. Contrast Media & Molecular Imaging 2018:1269830.

*)           Nejabat M, Leisser A, Karanikas G, Wadsak W, Mitterhauser M, Mayerhöfer M,  Kienbacher C, Trauner M, Hacker M, Haug AR. [11C]acetate PET as a tool for diagnosis of liver steatosis. Abdominal Radiology (NY). 2018;43:2963-2969.

*)           Gryglewski G, Seiger R, James GM, Godbersen GM, Komorowski A, Michenthaler P, Hahn A, Wadsak W, Mitterhauser M, Kasper S, Lanzenberger R. Spatial analysis and prediction of the human whole-brain transcriptome. Neuroimage 2018;176:259-267.

*)           Mayerhoefer ME, Jaeger U, Staber P, Raderer M, Wadsak W, Pfaff S, Kornauth C, Senn D, Weber M, Wester HJ, Skrabs C, Haug A. [68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary Results. Invest Radiol. 2018;53:403-408.

*)           Rischka L, Gryglewski G, Pfaff S, Vanicek T, Hienert M, Klöbl M, Hartenbach M, Haug A, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Hahn A. Reduced task durations in functional PET imaging with [18F]FDG approaching that of functional MRI. NeuroImage 2018;181:323-330.

*)           Philippe C, Zeilinger M, Dumanic M, Pichler F, Fetty L, Vraka C, Balber T, Wadsak W, Pallitsch K, Spreitzer H, Lanzenberger R, Hacker M, Mitterhauser M. SNAPshots of the MCHR1: A comparison between the PET-tracers [18F]FE@SNAP and [11C]SNAP-7941. Molecular Imaging and Biology 2018; Jun 13. doi: 10.1007/s11307-018-1212-0. [Epub ahead of print]

*)           Grubmüller B, Baltzer P, Hartenbach S, D’Andrea D, Helbich TH, Haug AR, Goldner GM, Wadsak W, Pfaff S, Mitterhauser M, Balber T, Berroteran-Infante N, Grahovac M, Babich J, Seitz C, Kramer G,  Susani M, Mazal P, Kenner L, Shariat SF, Hacker M, Hartenbach M. PSMA ligand PET/MRI for primary prostate cancer: Staging performance and clinical impact. Clinical Cancer Research 2018;24:6300-6307.

*)           Grubmüller B, Senn D, Kramer G, Baltzer P, D'Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, Shariat SF, Hacker M, Hartenbach M. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018 Dec 19. doi: 10.1007/s00259-018-4236-4. [Epub ahead of print]

*)           James GM, Gryglewski G, Vanicek T, Berroterán-Infante N, Philippe C, Kautzky A, Nics L, Vraka C, Godbersen GM, Unterholzner J, Sigurdardottir HL, Spies M, Seiger R, Kranz GS, Hahn A, Mitterhauser M, Wadsak W, Bauer A, Hacker M, Kasper S, Lanzenberger R. Parcellation of the Human Cerebral Cortex Based on Molecular Targets in the Serotonin System Quantified by Positron Emission Tomography In vivo. Cereb Cortex. 2019;29:372-382.

*)            Spies M, James GM, Vraka C, Philippe C, Hienert M, Gryglewski G, Komorowski A, Kautzky A, Silberbauer L, Pichler V, Kranz GS, Nics L, Balber T, Baldinger-Melich P, Vanicek T, Spurny B, Winkler-Pjrek E, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Winkler D. Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy. Transl Psychiatry. 2018;8:198.

*)           Bauer M, Karch R, Wulkersdorfer B, Philippe C, Nics L, Klebermass EM, Weber M, Poschner S, Haslacher H, Jaeger W, Tournier N, Wadsak W, Hacker M, Zeitlinger M, Langer OA. Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier. J Nucl Med. 2018 Sep 20. pii: jnumed.118.216432. doi: 10.2967/jnumed.118.216432. [Epub ahead of print]

*)           Bauer M, Traxl A, Matsuda A, Karch R, Philippe C, Nics L, Klebermass EM, Wulkersdorfer B, Weber M, Poschner S, Tournier N, Jäger W, Wadsak W, Hacker M, Wanek T, Zeitlinger M, Langer O. Effect of Rifampicin on the Distribution of [11C]Erlotinib to the Liver, a Translational PET Study in Humans and in Mice. Mol Pharm. 2018;15:4589-4598.

*)           Rischka L, Gryglewski G, Pfaff S, Vanicek T, Hienert M, Klöbl M, Hartenbach M, Haug A, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Hahn A. Reduced task durations in functional PET imaging with [18F]FDG approaching that of functional MRI. Neuroimage. 2018;181:323-330.

*)           Nics L, Steiner B, Klebermass EM, Philippe C, Mitterhauser M, Hacker M, Wadsak W. Speed matters to raise molar radioactivity: Fast HPLC shortens the quality control of C-11 PET-tracers. Nuclear Medicine and Biology 2018;57:28-33.

*)           Berroterán-Infante N, Balber T, Fuerlinger P, Bergmann M, Lanzenberger R, Hacker M, Mitterhauser M, Wadsak W. [18F]FEPPA: Improved Automated Radiosynthesis, Binding Affinity Profile and Preliminary in Vitro Evaluation in Colorectal Cancer. ACS Medicinal Chemistry Letters 2018; 9:177-181.

*)           Pfaff S, Philippe C, Pichler V, Hacker M, Mitterhauser M, Wadsak W. Microfluidic 68Ga-labeling: A proof of principle study. Dalton Transactions 2018;47:5997-6004.

*)           Philippe C, Mairinger S, Pichler V, Stanek J, Nics L, Mitterhauser M, Hacker M, Wanek T, Langer O, Wadsak W. Comparison of fully-automated radiosyntheses of [11C]erlotinib for preclinical and clinical use starting from in target produced [11C]CO2 or [11C]CH4. EJNMMI Radiopharm Chem. 2018;3(1):8.

*)           Pichler V, Berroteran-Infante N, Philippe C, Vraka C, Klebermass EM, Balber T, Pfaff S, Nics L, Mitterhauser M, Wadsak W. An overview on PET radiochemistry: part 1 - covalent labels - 18F, 11C, and 13N. The Journal of Nuclear Medicine 2018;59:1350-1354.

*)            Pichler V, Zenz T, Philippe C, Vraka V, Berroterán-Infante N, Pfaff S, Nics L, Ozenil M, Langer O, Willeit M, Traub-Weidinger T, Lanzenberger R, Mitterhauser M, Hacker M, Wadsak W. Molar activity - the bugaboo in 11C-radiochemistry: an explorative study using the gas phase method. Nuclear Medicine and Biology 2018;67:21-26.

*)           Pfaff S, Nehring T, Pichler V, Cardinale J, Mitterhauser M, Hacker M, Wadsak W. Development and evaluation of a rapid analysis for HEPES determination in 68Ga-radiotracers. EJNMMI Research. 2018;8:95.

*)            Pichler V, Vraka V, Berroterán-Infante N, Krcal A, Eidherr H, Traub-Weidinger T, Hacker M, Mitterhauser M, Wadsak W. L-[S-methyl-11C]methionine - an example of radiosynthetic optimization. Applied Radiation and Isotopes 2018;141:107-111.

*)           Andrzejewski P, Wengert G, Helbich TH, Magometschnigg H, Georg D, Hacker M, Baltzer P, Clauser P, Kapetas P, Georg P, Wadsak W, Pinker K. Multiparametric [18F]FDG/[18F]FMISO PET-MRI at 3T for Insights Into Breast Cancer Heterogeneity and Correlation with Patient Outcomes: First Clinical Experience. Contrast Media and Molecular Imaging 2019; in press.

*)           Kalina T, Berroterán-Infante N, Schmitl S, Vraka C, Hacker M, Mitterhauser M, Pallitsch K*, Wadsak W*. Synthesis and in vitro evaluation of new translocator protein ligands designed for positron emission tomography. Future Medicinal Chemistry 2019; in review.

*)           Vraka C, Pichler V, Berroterán-Infante N, Wollenweber T, Pillinger A, Hohensinner M, Fetty L, Beitzke D, Li X, Philippe C, Pallitsch K, Mitterhauser M, Hacker M, Wadsak W. Optimization of the automated synthesis of [11C]mHED – administered and apparent molar activities. Pharmaceuticals 2019; in review.

Nach dem Abitur am Ludwigsgymnasium in Straubing (Bayern) 1995 und dem Wehrdienst als Sanitäter 1996 absolvierte Alexander Haug sein Studium der Humanmedizin an der Ludwig-Maximilians-Universität München 2003 (Note 1,6). 2004 begann er seine Ausbildung zum Facharzt für Nuklearmedizin am Universitätsklinikum München und wurde 2009 zum Facharzt ernannt. Ab 2009 leitete er die Therapiestation einschließlich der ambulanten Nachsorgeambulanz. 2013 habilitierte er sich zum Thema Molekulare Bildgebung und Therapie neuroendokriner Tumoren und wurde von der Ludwig-Maximilians-Universität München mit der venia docendi ausgezeichnet. Seit 2013 ist er stellvertretender Direktor der Klinik für Nuklearmedizin am Universitätsklinikum AKH Wien, Leiter der Therapiestation und derzeit assoziierter Professor für Nuklearmedizin.

Seit 2019 leitet er zudem das CD-Labor für Applied Metabolomics, das sich mit der Kombination der Tumor-Genetik mit der molekularen Bildgebung beschäftigt. Insgesamt hat er sich als Principal Investigator erfolgreich um Drittmittel in Höhe von insgesamt 3.500.000€ einschließlich Mitteln der Europäischen Union beworben. Für seine Forschung erhielt er mehrere Auszeichnungen, darunter den Wolfgang-Becker-Preis der Bayerischen Gesellschaft für Nuklearmedizin 2011, den Preis des Young Professionals Committee – Clinical Sciences der Society of Nuclear Medicine (SNM) 2010 2. Platz, den Nuclear Oncology Council Young Investigator Award der Society of Nuclear Medicine 2010 3. Platz und zweimal den Alavi-Mandell Award der Society of Nuclear Medicine im Jahr 2016 als Senior Autor. Er hielt mehr als 100 eingeladene Vorträge hauptsächlich über die Therapie und Bildgebung von neuroendokrinen Tumoren, aber auch über Radionuklidtherapien und molekulare Bildgebung generell, und war Dozent mehrerer Kurse der European Association of Nuclear Medicine (EANM) und der Internationalen Atomenergiebehörde (IAEA). Er hat mehr als 120 wissenschaftliche Artikel in Fachzeitschriften veröffentlicht, die bislang über 5000 mal zitiert wurden. Er war Senior Supervisor für mehrere Diplomanden und Doktoranden an der Medizinischen Universität Wien. Er ist Vorsitzender des Ausschusses Radionuklidtherapie der Österreichischen Gesellschaft für Nuklearmedizin und Molekulare Bildgebung, Vertreter für Nuklearmedizin in der Österreichischen Gesellschaft für Neuroendokrine Tumore, Mitglied des Leitlinienausschusses der Deutschen Gesellschaft für Nuklearmedizin, sowie Mitglied der Arbeitsgruppe Radionuklidtherapie des Bundesamts für Strahlenschutz. Überdies ist er Mitglied des zertifizierten ENETS (Europäische Neuroendokrine Tumore Gesellschaft) Center of Excellence in Wien und ist ein international anerkannter Experte in der Diagnostik und Therapie von neuroendokrinen Tumoren.

Seit 2019	Leiter des Christian-Doppler-Labors für „applied metabolomics“
2016	Alavi-Mandell Award der Society of Nuclear Medicine als Senior Author, zweimal
Seit 2013	Stellvertretender Direktor der Klinik für Nuklearmedizin am Universitätsklinikum AKH Wien, Leiter der Therapiestation und assoziierter Professor für Nuklearmedizin
2013	Habilitation für Molekulare Bildgebung und Therapie neuroendokriner Tumoren, venia docendi an der Ludwig-Maximilians-Universität München
2011	Wolfgang-Becker-Preis der Bayerischen Gesellschaft für Nuklearmedizin
2010	Nuclear Oncology Council Young Investigator Award der Society of Nuclear Medicine, 3. Platz
2010	Preis des Young Professionals Committee - Clinical Sciences der Society of Nuclear Medicine (SNM), 2. Platz
Ab 2009	Leiter der Therapiestation inkl. ambulante Pflege
2009	Facharzt für Nuklearmedizin
2004-2009	Ausbildung in Nuklearmedizin am Universitätsklinikum München
2003	Abschluss an der Ludwig-Maximilians-Universität München, Humanmedizin
07/1995-12/1996	Militärdienst
05/1995	Abitur am Ludwigsgymnasium in Straubing, Bayern

2011      Wolfgang-Becker-Preis der Bayerischen Gesellschaft für Nuklearmedizin

2010      Award of the Young Professionals Committee - Clinical Sciences of the Society of Nuclear Medicine (SNM), 2. Platz

2010      Nuclear Oncology Council Young Investigator Award of Society of Nuclear Medicine, 3. Platz

2016       Alavi-Mandell Award der Society of Nuclear Medicine als Senior Autor, zweimal

Sazan Rasul, Tim Wollenweber, Lucia Zisser, Elisabeth Kretschmer-Chott, Bernhard Grubmüller, Gero Kramer, Shahrokh F Shariat, Harald Eidherr, Markus Mitterhauser, Chrysoula Vraka, Werner Langsteger, Marcus Hacker, Alexander R Haug. Response and Toxicity to the Second Course of 3 Cycles of 177 Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2021 May 20;13(10):2489. doi: 10.3390/cancers13102489.

 

Sazan Rasul, Markus Hartenbach, Tim Wollenweber, Elisabeth Kretschmer-Chott, Bernhard Grubmüller, Gero Kramer, Shahrokh Shariat, Wolfgang Wadsak, Markus Mitterhauser, Verena Pichler, Chrysoula Vraka, Marcus Hacker, Alexander R Haug. Prediction of response and survival after standardized treatment with 7400 MBq 177 Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2020 Oct 30. doi: 10.1007/s00259-020-05082-5. Online ahead of print

Haug AR. PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme? EJNMMI Res. 2020 Apr 15;10(1):35. doi: 10.1186/s13550-020-00623-3.

 

Rasul S, Hacker M, Kretschmer-Chott E, Leisser A, Grubmueller B, Kramer G, Shariat S, Wadsak W, Mitterhauser M, Hartenbach M, Haug AR. Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400MBq every four weeks. Eur J Nucl Med Mol Imaging, 2019 Nov 28. doi: 10.1007/s00259-019-04584-1. [Epub ahead of print]

 

Finn Edler von Eyben, Glenn Bauman, Rie von Eyben, Kambiz Rahbar, Cigdem Soydal, Alexander R Haug, Irene Virgolini, Harshad Kulkarni, Richard Baum, Giovanni Paganelli. Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis. Int J Mol Sci. 2020 Nov 28;21(23):E9054. doi: 10.3390/ijms21239054.

 

Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2017 Dec 28. doi: 10.1007/s00259-017-3882-2. [Epub ahead of print]

 

Sabet A, Haug AR, Eiden C, Auernhammer CJ, Simon B, Bartenstein P, Biersack HJ, Ezziddin S. Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis. Am J Nucl Med Mol Imaging. 2017 Apr 15;7(2):74-83. eCollection 2017.

 

Hörsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Miederer M, Schreckenberger M, Krause BJ, Bengel FM, Bartenstein P, Biersack HJ, Pöpperl G, Baum RP. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up. Eur J Cancer. 2016 May;58:41-51

 

Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Beuschlein F, Wängler B, Übleis C, Schmidt GP, Spitzweg C, Bartenstein P, Hacker M. 68Ga-DOTATATE PET/CT in the diagnosis of neuroendocrine tumor recurrence. Radiology. 2014 Feb;270(2):517-25

 

Haug A, Cindea-Drimus R, Auernhammer CJ, Reincke M, Wängler B, Uebleis C, Schmidt GP, Göke B, Bartenstein P, Hacker M. The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors.    J Nucl Med. 2012 Nov;53(11):1686-92

 

Haug AR, Rominger A, Mustafa M, Auernhammer C, Göke B, Schmidt GP, Wängler B, Cumming P, Bartenstein P, Hacker M. Treatment with octreotide does not reduce the tumor uptake of 68Ga[DOTA0, Tyr3]octreotate as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med. 2011 Nov;52(11):1679-83

 

Haug A, Auernhammer CJ, Wangler B, Tiling R, Schmidt G, Goke B, Bartenstein P, Popperl G. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2009;36:765-70.

 

Haug AR, Assmann G, Rist C, Tiling R, Schmidt GP, Bartenstein P, Hacker M. [Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT]. Radiologe 2010;50: 349-54.

 

Haug AR, Auernhammer CJ, Wangler B, Schmidt GP, Uebleis C, Goke B, Cumming P, Bartenstein P, Tiling R, Hacker M. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 2010;51: 1349-56.

 

Ilhan H, Fendler WP, Cyran CC, Spitzweg C, Auernhammer Cj, Gildehaus FJ, Bartenstein P, Angele MK, Haug AR. Impact of 68Ga-DOTATATE  PET/CT on the Surgical Management of Primary Neuroendocrine Tumors of the Pancreas or Ileum. Ann Surg Oncol. 2015 Jan;22(1):164-71

Haug AR, Bartenstein P. Peptide receptor radionuclide therapy of neuroendocrine tumours. Onkologe 2011 July; 17(7): 602-608.

Haug AR, Bartenstein P. [Gastroenteropancreatic neuroendocrine tumors : Diagnosis and therapy in nuclear medicine.] Internist (Berl). 2012 Feb;53(2):161-6.

Haug A. Somatostatinrezeptor-PET. Der Nuklearmediziner. 2018 41(3)

 

Koch W, Auernhammer CJ, Geisler J, Spitzweg C, Cyran CC, Ilhan H, Bartenstein P, Haug AR. Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: Prognostic stratification with Ga-68-DOTA-TATE PET. Mol Imaging. 2014;13:1-10

 

Wim Oyen, Francis Sundram, Alexander R Haug, Kalevi Kairemo, Valerie Lewington, Hanna Mäenpää, Jann Mortensen, Felix Mottaghy, Irene Virgolini, Joe M O'Sullivan, Dirk Wyndaele Radium-223 Dichloride (Ra-223) for the Treatment of Metastatic Castration-resistant Prostate Cancer: Optimizing Clinical Practice in Nuclear Medicine Centers. Journal of OncoPathology. 2015; 3(1)

 

Geiger S, Horster S, Haug AR, Hausmann A, Schlemmer M, Stemmler HJ. Suspected osseous recurrence visualized on a (68)Ga-DOTATATE PET/CT scan during the follow-up of a patient with a resected pulmonary carcinoid tumour. Nuklearmedizin. 2011;50(5):N57-9.

 

Hörsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Krause BJ, Schümichen C, Bengel FM, Knapp WH, Bartenstein P, Biersack HJ, Plöckinger U, Schwartz-Fuchs S, Baum RP. Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multi-institutional Cancer Registry. Recent Results Cancer Res. 2013;194:457-65

 

Schmid-Tannwald C, Schmid-Tannwald CM, Morelli JN, Neumann R, Haug AR, Jansen N, Nikolaou K, Schramm N, Reiser MF, Rist C. Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas. Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):897-907

Armbruster M, Zech CJ, Sourbron S, Ceelen F, Auernhammer CJ, Rist C, Haug A, Singnurkar A, Reiser MF, Sommer WH. Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms. J Magn Reson Imaging. 2014 Aug;40(2):457-66.

 

Ceelen F, Theisen D, de Albéniz XG, Auernhammer CJ, Haug AR, D'Anastasi M, Paprottka PM, Rist C, Reiser MF, Sommer WH. Towards new response criteria in neuroendocrine tumors: Which changes in MRI parameters are associated with longer progression-free survival after radioembolization of liver metastases? J Magn Reson Imaging. 2015 Feb;41(2):361-8

 

Klingenstein A, Haug AR, Miller C, Hintschich C. Ga-68-DOTA-TATE PET/CT for Discrimination of Tumors of the Optic Pathway. Orbit. 2015 Feb;34(1):16-22

 

Rachinger W, Stoecklein VM, Terpolilli NA , Haug AR, Ertl L , Pöschl J , Schüller U , Schichor C, Thon N, Tonn JC. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumorfree tissue. J Nucl Med. 2015 Mar;56(3):347-53

 

Capasso E, Durzu S, Piras S, Zandieh S, Knoll P, Haug A, Hacker M, Meleddu C, Mirzaei S. Role of 64CuCl2 PET/CT in staging of prostate cancer. Ann Nucl Med. 2015 Jul;29(6):482-8.

 

Leisser A, Pruscha K, Ubl U, Wadsak W, Mayerhöfer M, Mitterhauser M, Hacker M, Kramer G, Shariat S, Karanikas G, Hartenbach M, Haug AR. Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [11C]acetate PET as a prognostic marker. The Prostate. 2015 Nov;75(15):1760-7.

Spick C, Polanec SH, Mitterhauser M, Wadsak W, Anner P, Reiterits B, Haug AR, Hacker M, Beheshti M, Karanikas G. Detection of Bone Metastases Using 11C-Acetate PET in Patients with Prostate Cancer with Biochemical Recurrence. Anticancer Res. 2015 Dec;35(12):6787-91.

 

Ilhan H, Wang H, Gildehaus FJ, Wängler C, Herrler T, Todica A, Schlichtiger J, Cumming P, Bartenstein P, Hacker M, Haug AR. Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy. EJNMMI Res. 2016 Dec;6(1):64.

 

Berzaczy D, Giraudo C, Haug AR, Raderer M, Senn D, Karanikas G, Weber M, Mayerhoefer ME. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients. Clin Nucl Med. 2017 Jul 6. doi: 10.1097/RLU.0000000000001753. [Epub ahead of print]

 

Grubmüller B, Baltzer P, D'Andrea D, Korn S, Haug AR, Hacker M, Grubmüller KH, Goldner GM, Wadsak W, Pfaff S, Babich J, Seitz C, Fajkovic H, Susani M, Mazal P, Kramer G, Shariat SF, Hartenbach M. 68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making. Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):235-242

 

Leisser A, Nejabat M, Hartenbach M, Sareshgi RMA, Shariat SF, Kramer G, Krainer M,  Hacker M,  Haug AR. Analysis of hematological parameters as prognostic markers for toxicity and survival of 223Radium treatment. Oncotarget. 2018

 

Grubmüller B, Baltzer P, Hartenbach S, D'Andrea D, Helbich T, Haug A, Goldner G, Wadsak W, Pfaff S, Mitterhauser M, Balber T, Berroterán-Infante N, Grahovac M, Babich J, Seitz C, Kramer G, Susani M, Mazal P, Kenner L, Shariat S, Hacker M, Hartenbach M. PSMA ligand PET/MRI for primary prostate cancer: Staging performance and clinical impact. Clin Cancer Res. 2018 Aug 23. pii: clincanres.0768.2018. doi: 10.1158/1078-0432.CCR-18-0768. [Epub ahead of print]

 

Kiesewetter B, Duan H, Lamm W, Haug A, Riss P, Selberherr A, Scheuba C, Raderer M. Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs. Oncologist. 2018 Aug 31. pii: theoncologist.2018-0191. doi: 10.1634/theoncologist.2018-0191. [Epub ahead of print]

 

Grubmüller B, Senn D, Kramer G, Baltzer P, D'Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, Shariat SF, Hacker M, Hartenbach M. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019 May;46(5):1063-1072

 

Leisser A, Lukic K, Nejabat M, Wadsak W, Mitterhauser M, Mayerhöfer M,  Karnaikas G, Raderer M, Hacker M, Haug AR. Sex-differences in [68Ga]Ga-DOTANOC biodistribution. Nucl Med Biol.

 

Spindelböck W, Kump PK, Püspök A, Koch R, Mayerhöfer M, Haug A, Fritz E, Obermayer-Pietsch B, Raderer M, Tribl B. [Neuroendocrine tumors in daily gastroenterology and endoscopy - a practice manual]. Z Gastroenterol. 2019 ec;57(12):1493-1513. doi: 10.1055/a-1013-4279. Epub 2019 Dec 11.

 

Zellmer J, Yen HY, Kaiser L, Mille E, Gildehaus FJ, Böning G, Steiger K, Hacker M, Bartenstein P, Todica A, Haug AR, Ilhan H. Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats. EJNMMI Res. 2020 Apr 25;10(1):41

 

Sandra Barna, Alexander R Haug, Markus Hartenbach, Sazan Rasul, Bernhard Grubmüller, Gero Kramer, Matthias Blaickner. Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer. Clin Nucl Med. 2020 Sep;45(9):661-667.

 

Geisler J, Bartenstein P, Haug AR. Therapie neuroendokriner Tumoren mit radioaktiv markierten Somatostatinanaloga. Der Nuklearmediziner 2011; 34(4).

Haug A, Pfluger T, Schnabel PA, Zaba O. Management von Tumoren mit neuroendokriner Differenzierung. Onkologie. 2013; 36(Suppl 6):9-13